Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
Date:3/7/2013

y our comprehensive and integrated discovery and development services in China and increased demand for testing services for both biologics and medical devices in the United States.  Revenue growth of 22.5% year over year in Manufacturing Services was driven by increased demand for preclinical and clinical-trial materials in our research manufacturing business, which more than offset lower demand for advanced intermediates in our commercial manufacturing business. 

Full-year 2012 GAAP gross profit increased 17.1% year over year to $183.2 million due to 22.8% revenue growth, offset by lower gross margin.  Full-year 2012 GAAP gross margin decreased to 36.7% from 38.4% in full-year 2011.  Gross margin in Laboratory Services decreased year over year to 38.6% from 40.7% mainly due to increasing labor costs in China, appreciation of the RMB versus the U.S. dollar, investments in new businesses, and lower pricing in chemistry services, partially offset by improved productivity.  Gross margin in Manufacturing Services decreased year over year to 30.3% from 31.1% mainly due to lower capacity utilization in our commercial manufacturing business. 

Full-year 2012 GAAP operating income increased 6.7% year over year to $89.4 million due to the 17.1% growth in gross profit, partially offset by increased operating expenses from the hiring of new senior staff, increased share-based compensation expenses, and increased R&D expenses.  Operating margin decreased to 17.9% from 20.6% due to the lower gross margin and the increased operating expenses.

Full-year 2012 GAAP net income increased 6.9% year over year to $86.6 million due to the 6.7% increase in operating income and a 5.7% increase in other income / (expenses), net, driven by a gain on foreign-exchange forward contracts of $5.3 million, partially offset by a 4.7% increase in income tax expense.

Full-year 2012 GAAP diluted earnings per ADS increased 10.8% to $1
'/>"/>

SOURCE Wuxi PharmaTech Co. Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
2. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
3. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
4. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
5. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
6. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
7. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
8. WuXi PharmaTech Receives GLP Certificate from SFDA for Suzhou Toxicology Facility
9. WuXi PharmaTech Announces Second-Quarter 2012 Results
10. Pharmatech Oncology Receives Phase 2 SBIR Funding for Just-In-Time Enrollment Model
11. WuXi PharmaTech Announces First-Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Texas , Sept. 17, 2014  Lightbeam ... Direct Accountable Care Organization (Physician Direct ACO) to ... their physicians in providing better care while reducing ... Physician Direct Accountable Care Organization ... Network Services (OPNS). The OPNS mission is to ...
(Date:9/17/2014)... -- An analysis done by the CVS Health Research ... new and expensive treatment for Hepatitis C introduced in ... months (May through August 2014) there has been a ... suggests another surge of patients will begin therapy when ... and shorter duration are introduced in the Fall. ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
Breaking Medicine Technology:Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 2Physician Direct Accountable Care Organization Selects Lightbeam Health to Enable Better Care at a Lower Cost 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 2CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 3CVS Health Research Institute Provides First Look at Treatment with New Hepatitis C Therapies 4Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2
... Synteract, Inc ., a full-service contract ... training classes for CDISC , a global, ... the acquisition, exchange, submission and archive of clinical ... 21-24, 2012 at Synteract,s Carlsbad, Calif., headquarters. ...
... COLUMBUS, Ohio, Feb. 17, 2012  Chemical Abstracts Service ... Taylor & Francis, a leading publisher of scientific ... new experimental procedures for chemical reactions from three ... SciFinder®. (Logo: http://photos.prnewswire.com/prnh/20110418/MM84805 ) ...
Cached Medicine Technology:Synteract Hosting CDISC Classes on Regulatory Data Standards, Feb. 21-24, in California 2CAS and Taylor & Francis Collaborate to Improve Scientists' Access to Published Research 2
(Date:9/17/2014)... TX (PRWEB) September 17, 2014 North ... were recently granted several awards for their top-notch services. ... patient experience, orthopedic care and GYN surgery. , Hospital-wide, ... Safety Excellence Award™. They have received this award for ... among the top 5 percent in the nation for ...
(Date:9/17/2014)... (HealthDay News) -- A blood test that measures DNA ... a better assessment of the state of a man,s ... routinely, this blood test could reveal when treatment ... promoting tumor growth, the researchers suggested. "Our study ... advanced prostate cancer and often initially very effective started ...
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... Why are Asian Americans at higher risk of developing ... develop the disease at lower body weights? One part ... traditional high-fiber, low-fat Asian diets to current westernized diets, ... heritage, says George King, M.D., Senior Vice President and ... senior author of the study. , A Joslin randomized ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is ... on molecular diagnostics for conditions such as infectious diseases, ... IVD market value is projected to be worth around ... major drivers of the market’s growth include the shift ... by the explosion for raid and minimally-invasive diagnostic tools; ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center Receives Several Accolades 2Health News:DNA Blood Test Might Identify Status of Prostate Cancer 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 2Health News:In Joslin trial, Asian Americans lower insulin resistance on traditional diet 3Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3
... oncologists and urologists at the Kimmel Cancer Center at ... begun using a real-time system to implant radiation-emitting seeds ... made by Nucletron, a technology company based in The ... purposes so far, it ultimately will help with the ...
... chips, Japanese scientists have come up with the perfect recipe ... fat, reports Joanna Harries in Chemistry & Industry, the magazine ... Tokyo University of Technology studied how the structure of the ... water content and frying time they were able to suggest ...
... cancer (CRC) screening rates in primary care practices, according ... 2007 issue of CANCER, a peer-reviewed journal of the ... University in Philadelphia and co-authors found in primary care ... personalized behavioral intervention service offered to patients who are ...
... The following is a,statement from Alan Rosenbloom, President of ... the Sunday, Sept 23, New York Times story,entitled, "At ... nursing home data analyzed by the New York Times, ... segment of the nation,s long term,care ownership category, and ...
... How to Heal The World. (All overseas editions).,General Editor ... his first patient, the idea behind vaccines has not ... to wipe out the world,s worst,diseases are just as ... are making a difference, including a doctor who,s making ...
... Covance Inc. (NYSE:,CVD) today announced that it will ... 24 at 3:30 pm ET. Investors may access a ... order to register and,download any necessary software, please log ... Princeton, New Jersey, is one of the,world,s largest and ...
Cached Medicine News:Health News:Jefferson radiation oncologists use real-time system to plant 'seeds' against cancer 2Health News:Simple, personalized interventions improve colorectal cancer screening rates 2Health News:Statement from the Alliance for Quality Nursing Home Care 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 2Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 3Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 4Health News:NEWSWEEK International Editions: Highlights and Exclusives, Oct. 1, 2007 Issue 5
... Nebulizer Disposable Prefilled 28%-100% FIO 2 1000ML ... ,Our prefilled nebulizers provide unmatched performance and ease ... high-output aerosols adjustable from 28% to 100% FIO ... solutions: sterile water for inhalation, USP; 0.45% sodium ...
Respirgard II Nebulizer System with Acorn II Nebulizer, 7' (2 m) supply tubing, universal "antidrool" tee, mouthpiece, 6" (15 cm) aerosol tube, wye, one-way valve and expiratory filter...
... Graham-Field has been developing ... than 58 years. Our medical-surgical ... reputation for innovation, quality and ... brands include the Labtron® line ...
... modified nebulizer setups to deliver CNT and ... your patient is critical? OMNI~MAX has everything ... Heliox rescue therapy. In severe obstructive disease, ... of care in hospitals across the nation. ...
Medicine Products: